Current oral TKIs with FDA approved to treat advanced NSCLC patients whose tumors harbor sensitizing EGFR mutations include gefitinib, erlotinib (with or without ramucirumab), afatinib, dacomitinib and osimertinib. Here, EGFR is linked to non-small cell lung carcinoma.